Long Position on DYN @ $44.50 on 8/28/2024 (Momentum)

Dyne Therapeutics, Inc. (DYN), a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.

It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Entry Point: $44.50

Trading Range: $6.40 - $47.45

Stop Loss: $42.30

Target Price: $48.00

Position closed on 9/16/2024 at price of $42.30 with a -4.94% loss in 18 days.

Back to Portfolio